ponatinib 

ONCOLOGY, THERAPEUTICS

A monoclonal kinase inhibitor used to manage adults with accelerated, blast, or chronic phases of chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia which is resistant or intolerant to prior tyrosine kinase therapy. 

Adverse effects Ponatinib therapy increases the risk of arterial–cardiovascular, cerebrovascular–and peripheral vascular thrombosis, includingcongestive heart failure, fatal myocardial infarction; hepatotoxicty, liver failure and death, hypertension, and pancreatitis 

Synonyms Iclusig™ 

Reference Product literature, Ariad Pharmaceuticals